Model of the formation of streptozotocin-induced diabetes in Wiesenau pigs with assessment of its effectiveness and stability

BACKGROUND: Research aimed at creating and validating models of diabetes plays an important role in the development of new treatments for this disease. Large animal models may bridge the gap between basic research and clinical trials of new technologies for the treatment of insulin deficiency. At the moment, the most popular model is streptozotocin-induced diabetes. However, different species and breeds of animals respond differently to streptozotocin. Thus, although models already exist in different breeds of pigs, verification of the Wiesenau pig model of streptozotocin-induced diabetes is an important task, since this breed has not yet been used, and it is also one of the most accessible breeds of laboratory pigs in the world. Russia.

AIM: To reproduce the model of streptozotocin-induced diabetes in Wiesenau pigs with correction of hyperglycemia by insulin therapy and evaluate its stability and compliance with the experimental model of type 1 diabetes.

MATERIALS AND METHODS: The study was performed on 6 Wiesenau pigs. Diabetes was induced by intravenous administration of streptozotocin (150 mg/kg). Blood glucose concentration was determined with a glucometer and a continuous glucose monitoring system was used. The content of insulin in the blood was determined by enzyme-linked immunosorbent assay (Cloud-clone corp). The success of diabetes induction was confirmed by a glucose tolerance test. Seven days after the injection of STZ, insulin therapy was initiated and continued for three months. Insulin therapy was carried out for three months. 3 months after induction, a histological and immunohistochemical study of the condition of the pancreatic islets was carried out.

RESULTS: A study in Wiesenau pigs showed that a dose of 150 mg/kg streptozotocin was safe and effective in inducing diabetes in 67% of cases. An optimal individual insulin therapy protocol was selected, which successfully reduces blood glucose levels to normal values. This model of streptozotocin-induced diabetes in Wiesenau pigs is stable for 90 days and can be used to study new antidiabetic agents.

CONCLUSION: A model of STZ-induced diabetes has been established in Wiesenau pigs. The stability of the model has been confirmed under conditions of glucose toxicity alleviation through insulin therapy.

1. Renner S, Blutke A, Clauss S, et al. Porcine models for studying complications and organ crosstalk in diabetes mellitus. Cell Tissue Res. 2020;380(2):341-378. doi: https://doi.org/10.1007/s00441-019-03158-9

2. Joshi K, Katam T, Hegde A, et al. Pigs: Large Animal Preclinical Cancer Models. World J Oncol. 2024;15(2):149-168. doi: https://doi.org/10.14740/wjon1763

3. Zettler S, Renner S, Kemter E, et al. A decade of experience with genetically tailored pig models for diabetes and metabolic research. Anim Reprod. 2020;17(3):e20200064. doi: https://doi.org/10.1590/1984-3143-AR2020-0064

4. Ighodaro OM, Adeosun AM, Akinloye OA. Alloxan-induced diabetes, a common model for evaluating the glycemic-control potential of therapeutic compounds and plants extracts in experimental studies. Medicina (Kaunas). 2017;53(6):365-374. doi: https://doi.org/10.1016/j.medici.2018.02.001

5. Pandey S, Chmelir T, Chottova Dvorakova M. Animal Models in Diabetic Research-History, Presence, and Future Perspectives. Biomedicines. 2023;11(10):2852. Published 2023 Oct 20. doi: https://doi.org/10.3390/biomedicines11102852

6. Larsen MO, Rolin B. Use of the Göttingen Minipig as a Model of Diabetes, with Special Focus on Type 1 Diabetes Research. ILAR Journal / National Research Council, Institute of Laboratory Animal Resources. 2004;45(3):303-313. doi: https://doi.org/10.1093/ilar.45.3.303

7. Niu M, Liu Y, Xiang L, et al. Long-term case study of a Wuzhishan miniature pig with diabetes. Animal Model Exp Med. 2020;3(1):22-31. doi: https://doi.org/10.1002/ame2.12098

8. Jensen-Waern M, Andersson M, Kruse R, et al. Effects of streptozotocin-induced diabetes in domestic pigs with focus on the amino acid metabolism. Lab Anim. 2009;43(3):249-254. doi: https://doi.org/10.1258/la.2008.008069

9. Manell EA, Rydén A, Hedenqvist P, Jacobson M, Jensen-Waern M. Insulin treatment of streptozotocin-induced diabetes reestablishes the patterns in carbohydrate, fat and amino acid metabolisms in growing pigs. Lab Anim. 2014;48(3):261-269. doi: https://doi.org/10.1177/0023677213517683

10. Strauss A, Moskalenko V, Tiurbe C, et al. Goettingen Minipigs (GMP): Comparison of Two Different Models for Inducing Diabetes. Diabetol Metab Syndr. 2012;4:7. doi: https://doi.org/10.1186/1758-5996-4-7

11. Mésangeau D, Laude D, Elghozi JL. Early detection of cardiovascular autonomic neuropathy in diabetic pigs using blood pressure and heart rate variability. Cardiovasc Res. 2000;45(4):889-899. doi: https://doi.org/10.1016/s0008-6363(99)00406-x

12. Furman BL. Streptozotocin‐induced diabetic models in mice and rats. Curr Protoc Pharmacol. 2015:70(1):5.47.1-5.47.20. doi: https://doi.org/10.1002/0471141755.ph0547s70

13. Hara H, Lin YJ, Zhu X, et al. Safe induction of diabetes by high-dose streptozotocin in pigs [published correction appears in Pancreas. 2008 Apr;36(3):328. Balamarugan, A N [corrected to Balamurugan, A N]]. Pancreas. 2008;36(1):31-38. doi: https://doi.org/10.1097/mpa.0b013e3181452886

14. Koopmans SJ, Mroz Z, Dekker R, Corbijn H, Ackermans M, Sauerwein H. Association of insulin resistance with hyperglycemia in streptozotocin-diabetic pigs: effects of metformin at isoenergetic feeding in a type 2-like diabetic pig model. Metabolism. 2006;55(7):960-971. doi: https://doi.org/10.1016/j.metabol.2006.03.004

15. Deeds MC, Anderson JM, Armstrong AS, et al. Single dose streptozotocin-induced diabetes: considerations for study design in islet transplantation models. Lab Anim. 2011;45(3):131-140. doi: https://doi.org/10.1258/la.2010.010090

16. Wei M, Ong L, Smith MT, et al. The streptozotocindiabetic rat as a model of the chronic complications of human diabetes. Heart Lung Circ. 2023;12(1):44-50. doi: https://doi.org/10.1046/j.1444-2892.2003.00160.x

17. Gvazava IG, Kosykh AV, Rogovaya OS, et al. A Simplified Streptozotocin-Induced Diabetes Model in Nude Mice. Acta Naturae. 2020;12(4):98-104. doi: https://doi.org/10.32607/actanaturae.11202

18. Lee DY, Yang K, Lee S, et al. Optimization of monomethoxypolyethylene glycol grafting on the pancreatic islet capsules. J Biomed Mater Res. 2002;62(3):372-377. doi: https://doi.org/10.1002/jbm.10246

19. Kobayashi K, Kobayashi N, Okitsu T, et al. Development of a porcine model of type 1 diabetes by total pancreatectomy and establishment of a glucose tolerance evaluation method. Artif Organs. 2004;28(11):1035-1042. doi: https://doi.org/10.1111/j.1525-1594.2004.00002.x

20. Ludwig B, Wolf E, Schönmann U, Ludwig S. Large Animal Models of Diabetes. Methods Mol Biol. 2020;2128:115-134. doi: https://doi.org/10.1007/978-1-0716-0385-7_9

21. Grossman EJ, Lee DD, Tao J, et al. Glycemic control promotes pancreatic beta-cell regeneration in streptozotocin-induced diabetic mice. PLoS One. 2010;5(1):e8749. Published 2010 Jan 18. doi: https://doi.org/10.1371/journal.pone.0008749

22. Yin D, Tao J, Lee DD, et al. Recovery of islet beta-cell function in streptozotocin- induced diabetic mice: an indirect role for the spleen. Diabetes. 2006;55(12):3256-3263. doi: https://doi.org/10.2337/db05-1275

23. Nalin L, Selvaraju RK, Velikyan I, et al. Positron emission tomography imaging of the glucagon-like peptide-1 receptor in healthy and streptozotocin-induced diabetic pigs. Eur J Nucl Med Mol Imaging. 2014;41(9):1800-1810. doi: https://doi.org/10.1007/s00259-014-2745-3